DOCSLIB.ORG

Supplementary Table 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table 2 : List of the 336 genes regulated in human adipose tissue during 3 hours hyperglycemic clamp UGCluster Name Symbol Fold Change Cytoband Response to stress Hs.322430 NDRG family member 4 NDRG4 1.41 16q21-q22.1 Hs.9613 Angiopoietin-like 4 ANGPTL4 -1.46 19p13.3 Hs.274363 Neuroglobin NGB -1.47 14q24 Hs.433213 Hypoxia-inducible protein 2 HIG2 -1.48 7q32.1 Hs.150837 Thioredoxin domain containing 5 TXNDC5 -1.52 6p24.3 Hs.523836 Glutathione S-transferase pi GSTP1 -1.54 11q13 Hs.523012 DNA-damage-inducible transcript 4 DDIT4 -1.96 10pter-q26.12 Immune response, cytokines & related Hs.478275 Tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 1.41 3q26 Hs.2164 Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) PPBP 1.41 4q12-q13 Hs.375108 CD24 molecule CD24 1.41 6q21 Hs.534322 Major histocompatibility complex, class II, DR beta 1 HLA-DRB1 1.41 6p21.3 Hs.278391 Toll-like receptor adaptor molecule 2 TICAM2 1.40 5q23.1 Hs.579550 Deleted in colorectal carcinoma DCC -1.47 18q21.3 Hs.232543 Programmed cell death 4 (neoplastic transformation inhibitor) PDCD4 -1.49 10q24 Hs.499674 Mannose-binding lectin (protein C) 2, soluble MBL2 -1.81 10q11.2-q21 Hs.80395 Mal, T-cell differentiation protein MAL -1.89 2cen-q13 Hs.583348 Inhibin, beta A (activin A, activin AB alpha polypeptide) INHBA -2.07 7p15-p13 Hs.522572 B-lymphocyte antigen precursor RP13-297E16.1 -2.52 Xp22.32 Hs.276925 GTP binding protein 1 GTPBP1 -2.24 22q13.1 Circulating active peptides Hs.432400 Agouti signaling protein, nonagouti homolog (mouse) ASIP -1.42 20q11.2-q12 Hs.160562 Insulin-like growth factor 1 (somatomedin C) IGF1 -1.45 12q22-q23 Hs.441047 Adrenomedullin ADM -1.45 11p15.4 Hs.1103 Transforming growth factor, beta 1 TGFB1 -1.49 19q13.2 Hs.156979 Interleukin 17B IL17B -2.05 5q32-34 Hs.2561 Nerve growth factor, beta polypeptide NGFB -2.46 1p13.1 Receptors Hs.369592 Thyroid adenoma associated THADA 1.46 2p21 Hs.525666 Olfactory receptor, family 4, subfamily N, member 4 OR4N4 1.42 15q11.2 Hs.52931 Adrenergic, alpha-1A-, receptor ADRA1A 1.40 8p21-p11.2 Hs.101480 AP1 gamma subunit binding protein 1 AP1GBP1 -1.42 17q12 Hs.155048 Basal cell adhesion molecule (Lutheran blood group) BCAM -1.43 19q13.2 Hs.438311 Angiotensin II receptor-like 1 AGTRL1 -1.53 11q12 Hs.72550 Hyaluronan-mediated motility receptor (RHAMM) HMMR -1.55 5q33.2-qter Hs.171844 Poliovirus receptor PVR -1.60 19q13.2 Hs.525105 SLIT and NTRK-like family, member 6 SLITRK6 -1.68 13q31.1 Endothelial differentiation, lysophosphatidic acid G-protein- Hs.515061 EDG6 -1.76 19p13.3 coupled receptor, 6 Hs.109514 Ryanodine receptor 2 (cardiac) RYR2 -1.77 1q42.1-q43 Hs.178066 Membrane-spanning 4-domains, subfamily A, member 5 MS4A5 -1.78 11q12 Signaling pathways Protein phosphatases Hs.19281 Protein tyrosine phosphatase, non-receptor type 14 PTPN14 -1.44 1q32.2 Hs.291000 Protein phosphatase 1K (PP2C domain containing) PPM1K -1.46 4q22.1 Protein phosphatase 2 (formerly 2A), regulatory subunit A (PR Hs.584790 PPP2R1B -1.60 11q23.2 65), beta isoform Hs.106019 Protein phosphatase 1, regulatory subunit 10 PPP1R10 -1.62 6p21.3 Hs.148340 Protein tyrosine phosphatase, receptor type, G PTPRG -1.87 3p21-p14 Protein kinases Hs.164267 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 DYRK3 1.46 1q32.1 Hs.7200 NIMA (never in mitosis gene a)- related kinase 9 NEK9 -1.45 14q24.3 Hs.36566 LIM domain kinase 1 LIMK1 -1.47 7q11.23 Hs.431550 Mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 -1.49 2q11.2-q12 Hs.291623 TAO kinase 2 TAOK2 -1.63 16p11.2 Hs.468878 AP2 associated kinase 1 AAK1 -1.63 2p24.3-p14 Hs.531704 Protein kinase C, alpha PRKCA -1.67 17q22-q23.2 Hs.234521 Mitogen-activated protein kinase-activated protein kinase 3 MAPKAPK3 -1.73 3p21.3 Hs.133534 Kinase suppressor of ras 1 KSR1 -1.85 17q11.1 Calcium/calmodulin-dependent serine protein kinase (MAGUK Hs.495984 CASK -2.16 Xp11.4 family) Hs.478199 Protein kinase C, iota PRKCI -2.28 3q26.3 Hs.541273 V-akt murine thymoma viral oncogene homolog 2 AKT2 -2.46 19q13.1-q13.2 Hs.495731 BMX non-receptor tyrosine kinase BMX -2.53 Xp22.2 Hs.466743 Mitogen-activated protein kinase kinase kinase 10 MAP3K10 -3.06 19q13.2 cAMP Pathway Hs.194350 Protein kinase, cAMP-dependent, catalytic, alpha PRKACA -1.34 19p13.1 Hs.129493 Adenylate cyclase 5 ADCY5 -1.43 3q13.2-q21 Hs.572993 2'-phosphodiesterase 2'-PDE -1.46 3p14.3 Hs.132902 CAP, adenylate cyclase-associated protein, 2 (yeast) CAP2 -1.47 6p22.3 Hs.486483 A kinase (PRKA) anchor protein 7 AKAP7 -1.48 6q23 Hs.170839 Phospholamban PLN -1.61 6q22.1 Others signaling pathways Hs.6136 Rho GTPase activating protein 20 ARHGAP20 1.47 11q22.3-q23.1 Hs.233495 Pleckstrin homology domain containing, family A member 8 PLEKHA8 1.45 7p21-p11.2 Hs.125293 RasGEF domain family, member 1A RASGEF1A 1.41 10q11.21 Hs.535257 Centaurin, beta 5 CENTB5 -1.41 Hs.778 Guanylate cyclase activator 2A (guanylin) GUCA2A -1.41 1p35-p34 Hs.469593 LIM and senescent cell antigen-like domains 1 LIMS1 -1.42 2q12.3-q13 Hs.477142 Phosphatidic acid phosphatase type 2B PPAP2B -1.43 1pter-p22.1 Hs.121593 Centaurin, alpha 1 CENTA1 -1.43 7p22.3 Hs.465506 Phosphatidic acid phosphatase type 2C PPAP2C -1.43 19p13 Hs.531752 RAN binding protein 3 RANBP3 -1.43 19p13.3 Hs.303208 SH2 domain containing 4A SH2D4A -1.46 8p21.2 Hs.442344 Insulin receptor substrate 2 IRS2 -1.48 13q34 Hs.225356 CDC42 effector protein (Rho GTPase binding) 1 CDC42EP1 -1.49 22q13.1 Hs.32966 Guanylate cyclase activator 2B (uroguanylin) GUCA2B -1.52 1p34-p33 Hs.302435 Centaurin, gamma 1 CENTG1 -1.54 12q14.1 Hs.522378 DAB2 interacting protein DAB2IP -1.57 9q33.1-q33.3 Hs.50640 Suppressor of cytokine signaling 1 SOCS1 -1.60 16p13.13 Pleckstrin homology domain containing, family G (with RhoGef Hs.1116 PLEKHG6 -1.78 12p13.31 domain) member 6 Pleckstrin homology domain containing, family G (with RhoGef Hs.189781 PLEKHG1 -1.82 6q25.1 domain) member 1 Hs.515469 Vasodilator-stimulated phosphoprotein VASP -1.91 19q13.2-q13.3 Hs.368808 EH-domain containing 3 EHD3 -1.92 2p21 Hs.133044 Raptor raptor -2.10 17q25.3 Hs.435019 Neurexophilin 2 NXPH2 -2.21 2q22.1 Hs.521482 Src homology 2 domain containing adaptor protein B SHB -2.25 9p12-p11 Enzymes Carbohydrate metabolism Hs.591588 Hexokinase 2 HK2 1.65 2p13 Hs.26010 Phosphofructokinase, platelet PFKP 1.40 10p15.3-p15.2 Phosphorylase, glycogen; muscle (McArdle syndrome, glycogen Hs.154084 PYGM -1.40 11q12-q13.2 storage disease type V) Hs.411695 Hexokinase 3 (white cell) HK3 -1.70 5q35.2 Hs.8364 Pyruvate dehydrogenase kinase, isozyme 4 PDK4 -2.17 7q21.3-q22.1 Hs.195471 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 PFKFB3 -2.23 10p14-p15 Hs.590891 Phosphoglucomutase 3 PGM3 -2.69 6q14.1-q15 Lipid metabolism Hs.122038 Acyl-CoA thioesterase 6 ACOT6 1.46 14q24.3 Hs.128598 3-hydroxyisobutyryl-Coenzyme A hydrolase HIBCH 1.41 2q32.2 Hs.303980 Cytochrome P450, family 11, subfamily A, polypeptide 1 CYP11A1 -1.45 15q23-q24 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic Hs.320151 AGPAT2 -1.49 9q34.3 acid acyltransferase, beta) Hs.50727 Hydroxysteroid (17-beta) dehydrogenase 1 HSD17B1 -1.51 17q11-q21 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta- Hs.364941 HSD3B1 -1.65 1p13.1 isomerase 1 ATPase Hs.34114 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide ATP1A2 1.58 1q21-q23 Hs.370834 ATPase family, AAA domain containing 2 ATAD2 1.43 8q24.13 Hs.306212 ATPase, Class I, type 8B, member 3 ATP8B3 -1.90 19p13.3 Others enzymes Hs.67201 5', 3'-nucleotidase, cytosolic NT5C 1.48 17q25.1 Hs.524579 Lysozyme (renal amyloidosis) LYZ 1.48 12q15 Hs.104347 2-aminoadipic 6-semialdehyde dehydrogenase AASDH 1.43 4q12 Hs.284491 Pyridoxal (pyridoxine, vitamin B6) kinase PDXK 1.42 21q22.3 Hs.75372 N-acetylgalactosaminidase, alpha- NAGA -1.47 22q13-qter Hs.500750 Heparanase 2 HPSE2 -1.49 10q23-q24 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member Hs.567342 SULT1A1 -1.49 16p12.1 1 Hs.512181 Spermidine/spermine N1-acetyl transferase-like 1 SATL1 -1.57 Xq21.1 Hs.458332 Pyrroline-5-carboxylate reductase 1 PYCR1 -1.81 17q25.3 Hs.369762 Enolase superfamily member 1 ENOSF1 -1.88 18p11.32 Hs.431417 Arylalkylamine N-acetyltransferase AANAT -2.30 17q25 Hs.463466 Carbonic anhydrase X CA10 -2.32 17q21 Hs.159525 Cell growth regulator with EF-hand domain 1 CGREF1 -2.62 2p23.3 Structural proteins & cytoskeleton Hs.520554 Tubulin tyrosine ligase-like family, member 2 TTLL2 1.48 6q27 Hs.60480 Keratin associated protein 19-3 KRTAP19-3 1.45 21q22.1 Hs.407580 Plakophilin 4 PKP4 -1.42 2q23-q31 Hs.2785 Keratin 17 KRT17 -1.43 17q12-q21 Hs.418012 Collagen, type IX, alpha 2 COL9A2 -1.46 1p33-p32 Hs.497350 Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) PKP1 -1.47 1q32 Hs.432390 Dynein, axonemal, heavy polypeptide 11 DNAH11 -1.51 7p21 Hs.534797 Catenin (cadherin-associated protein), alpha 1, 102kDa CTNNA1 -1.57 5q31 Hs.1076 Small proline-rich protein 1B (cornifin) SPRR1B -1.57 1q21-q22 Hs.381181 Coiled-coil domain containing 96 CCDC96 -1.60 4p16.1 Hs.125133 Hermansky-Pudlak syndrome 6 HPS6 -1.61 10q24.32 Fascin homolog 2, actin-bundling protein, retinal Hs.118555 FSCN2 -1.63 17q25 (Strongylocentrotus purpuratus) Hs.25640 Claudin 3 CLDN3 -1.67 7q11.23 Hs.487036 Myosin VC MYO5C -1.67 15q21 Microtubule associated monoxygenase, calponin and LIM domain Hs.501928 MICAL2 -1.67 11p15.3 containing 2 Hs.446867 Formin 1 FMN1 -1.69 15q13.3 Hs.34780 Doublecortex; lissencephaly, X-linked (doublecortin) DCX -1.70 Xq22.3-q23 Hs.499745 Myosin, heavy polypeptide 2, skeletal muscle, adult MYH2 -1.71 17p13.1 Hs.513915 Claudin 7 CLDN7 -1.71 17p13
Recommended publications
  • PARSANA-DISSERTATION-2020.Pdf

    PARSANA-DISSERTATION-2020.Pdf

    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
  • Distinguishing Pleiotropy from Linked QTL Between Milk Production Traits

    Distinguishing Pleiotropy from Linked QTL Between Milk Production Traits

    Cai et al. Genet Sel Evol (2020) 52:19 https://doi.org/10.1186/s12711-020-00538-6 Genetics Selection Evolution RESEARCH ARTICLE Open Access Distinguishing pleiotropy from linked QTL between milk production traits and mastitis resistance in Nordic Holstein cattle Zexi Cai1*†, Magdalena Dusza2†, Bernt Guldbrandtsen1, Mogens Sandø Lund1 and Goutam Sahana1 Abstract Background: Production and health traits are central in cattle breeding. Advances in next-generation sequencing technologies and genotype imputation have increased the resolution of gene mapping based on genome-wide association studies (GWAS). Thus, numerous candidate genes that afect milk yield, milk composition, and mastitis resistance in dairy cattle are reported in the literature. Efect-bearing variants often afect multiple traits. Because the detection of overlapping quantitative trait loci (QTL) regions from single-trait GWAS is too inaccurate and subjective, multi-trait analysis is a better approach to detect pleiotropic efects of variants in candidate genes. However, large sample sizes are required to achieve sufcient power. Multi-trait meta-analysis is one approach to deal with this prob- lem. Thus, we performed two multi-trait meta-analyses, one for three milk production traits (milk yield, protein yield and fat yield), and one for milk yield and mastitis resistance. Results: For highly correlated traits, the power to detect pleiotropy was increased by multi-trait meta-analysis com- pared with the subjective assessment of overlapping of single-trait QTL confdence intervals. Pleiotropic efects of lead single nucleotide polymorphisms (SNPs) that were detected from the multi-trait meta-analysis were confrmed by bivariate association analysis. The previously reported pleiotropic efects of variants within the DGAT1 and MGST1 genes on three milk production traits, and pleiotropic efects of variants in GHR on milk yield and fat yield were con- frmed.
  • Phospholipase C-Related Catalytically Inactive Protein: a Novel Signaling Molecule for Modulating Fat Metabolism and Energy Expenditure

    Phospholipase C-Related Catalytically Inactive Protein: a Novel Signaling Molecule for Modulating Fat Metabolism and Energy Expenditure

    Journal of Oral Biosciences 61 (2019) 65e72 Contents lists available at ScienceDirect Journal of Oral Biosciences journal homepage: www.elsevier.com/locate/job Review Phospholipase C-related catalytically inactive protein: A novel signaling molecule for modulating fat metabolism and energy expenditure * Takashi Kanematsu a, b, , Kana Oue a, c, Toshiya Okumura a, Kae Harada a, 1, Yosuke Yamawaki a, 2, Satoshi Asano a, Akiko Mizokami d, Masahiro Irifune c, Masato Hirata e a Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan b Department of Cell Biology and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan c Department of Dental Anesthesiology, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734- 8553, Japan d OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan e Fukuoka Dental College, Fukuoka, 814-0193, Japan article info abstract Article history: Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose Received 16 March 2019 tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 Received in revised form diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong 17 April 2019 evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and Accepted 19 April 2019 improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and Available online 15 May 2019 high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti- obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been Keywords: Adipose tissue developed.
  • Molecular Characterization of Acute Myeloid Leukemia by Next Generation Sequencing: Identification of Novel Biomarkers and Targets of Personalized Therapies

    Molecular Characterization of Acute Myeloid Leukemia by Next Generation Sequencing: Identification of Novel Biomarkers and Targets of Personalized Therapies

    Alma Mater Studiorum – Università di Bologna Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Dottorato di Ricerca in Oncologia, Ematologia e Patologia XXX Ciclo Settore Scientifico Disciplinare: MED/15 Settore Concorsuale:06/D3 Molecular characterization of acute myeloid leukemia by Next Generation Sequencing: identification of novel biomarkers and targets of personalized therapies Presentata da: Antonella Padella Coordinatore Prof. Pier-Luigi Lollini Supervisore: Prof. Giovanni Martinelli Esame finale anno 2018 Abstract Acute myeloid leukemia (AML) is a hematopoietic neoplasm that affects myeloid progenitor cells and it is one of the malignancies best studied by next generation sequencing (NGS), showing a highly heterogeneous genetic background. The aim of the study was to characterize the molecular landscape of 2 subgroups of AML patients carrying either chromosomal number alterations (i.e. aneuploidy) or rare fusion genes. We performed whole exome sequencing and we integrated the mutational data with transcriptomic and copy number analysis. We identified the cell cycle, the protein degradation, response to reactive oxygen species, energy metabolism and biosynthetic process as the pathways mostly targeted by alterations in aneuploid AML. Moreover, we identified a 3-gene expression signature including RAD50, PLK1 and CDC20 that characterize this subgroup. Taking advantage of RNA sequencing we aimed at the discovery of novel and rare gene fusions. We detected 9 rare chimeric transcripts, of which partner genes were transcription factors (ZEB2, BCL11B and MAFK) or tumor suppressors (SAV1 and PUF60) rarely translocated across cancer types. Moreover, we detected cryptic events hiding the loss of NF1 and WT1, two recurrently altered genes in AML. Finally, we explored the oncogenic potential of the ZEB2-BCL11B fusion, which revealed no transforming ability in vitro.
  • The Protein Phosphatase PP2A Plays Multiple Roles in Plant Development by Regulation of Vesicle Traffic—Facts and Questions

    The Protein Phosphatase PP2A Plays Multiple Roles in Plant Development by Regulation of Vesicle Traffic—Facts and Questions

    International Journal of Molecular Sciences Review The Protein Phosphatase PP2A Plays Multiple Roles in Plant Development by Regulation of Vesicle Traffic—Facts and Questions Csaba Máthé *, Márta M-Hamvas, Csongor Freytag and Tamás Garda Department of Botany, Faculty of Science and Technology, University of Debrecen, H-4032 Debrecen, Hungary; [email protected] (M.M.-H.); [email protected] (C.F.); [email protected] (T.G.) * Correspondence: [email protected] Abstract: The protein phosphatase PP2A is essential for the control of integrated eukaryotic cell functioning. Several cellular and developmental events, e.g., plant growth regulator (PGR) mediated signaling pathways are regulated by reversible phosphorylation of vesicle traffic proteins. Reviewing present knowledge on the relevant role of PP2A is timely. We discuss three aspects: (1) PP2A regulates microtubule-mediated vesicle delivery during cell plate assembly. PP2A dephosphorylates members of the microtubule associated protein family MAP65, promoting their binding to microtubules. Regulation of phosphatase activity leads to changes in microtubule organization, which affects vesicle traffic towards cell plate and vesicle fusion to build the new cell wall between dividing cells. (2) PP2A-mediated inhibition of target of rapamycin complex (TORC) dependent signaling pathways contributes to autophagy and this has possible connections to the brassinosteroid signaling pathway. (3) Transcytosis of vesicles transporting PIN auxin efflux carriers. PP2A regulates vesicle localization and recycling of PINs related to GNOM (a GTP–GDP exchange factor) mediated pathways. The proper intracellular traffic of PINs is essential for auxin distribution in the plant body, thus in whole Citation: Máthé, C.; M-Hamvas, M.; plant development.
  • Studies on Cellular Nutrient Responses and Protein Degradation

    Studies on Cellular Nutrient Responses and Protein Degradation

    STUDIES ON CELLULAR NUTRIENT RESPONSES AND PROTEIN DEGRADATION APPROVED BY SUPERVISORY COMMITTEE Melanie Cobb, Ph.D. (Mentor) Joel Goodman, Ph.D. (Chair) Paul Sternweis, Ph.D. Joseph Albanesi, Ph.D. DEDICATION: I dedicate this dissertation to my parents and grandparents, for inspiring me to pursue science, and for their unconditional love and support. STUDIES ON CELLULAR NUTRIENT RESPONSES AND PROTEIN DEGRADATION by ANWESHA GHOSH DISSERTATION / THESIS Presented to the Faculty of the Graduate School of Biomedical Sciences The University of Texas Southwestern Medical Center at Dallas In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY / MASTER OF SCIENCE / MASTER OF ARTS The University of Texas Southwestern Medical Center at Dallas Dallas, Texas August, 2015 Copyright by Anwesha Ghosh, 2015 All Rights Reserved iv STUDIES ON CELLULAR NUTRIENT RESPONSES AND PROTEIN DEGRADATION Publication No. Anwesha Ghosh The University of Texas Southwestern Medical Center at Dallas, Graduation Year Supervising Professor: Melanie H. Cobb (Ph.D.) I have worked on two projects. The first project investigates mechanisms involved in cellular responses to amino acids. Amino-acid abundance promotes protein synthesis and cell growth via activation of the protein kinase mTOR, while amino-acid deprivation promotes protein degradation by autophagy. The heterodimeric G protein coupled receptor (GPCR) T1R1-T1R3 can act as an extracellular sensor for amino acids, promoting mTOR activity while repressing autophagy in cells. Quantitative PCR analysis revealed that T1R3 depletion increases mRNA expression of amino acid transporters as a compensatory mechanism induced by perceived starvation. The arrestin proteins can bind GPCRs to mediate their internalization or to facilitate downstream signaling.
  • Noelia Díaz Blanco

    Noelia Díaz Blanco

    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
  • The Regulatory Roles of Phosphatases in Cancer

    The Regulatory Roles of Phosphatases in Cancer

    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • An Advance About the Genetic Causes of Epilepsy

    An Advance About the Genetic Causes of Epilepsy

    E3S Web of Conferences 271, 03068 (2021) https://doi.org/10.1051/e3sconf/202127103068 ICEPE 2021 An advance about the genetic causes of epilepsy Yu Sun1, a, *, †, Licheng Lu2, b, *, †, Lanxin Li3, c, *, †, Jingbo Wang4, d, *, † 1The School of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801-3633, US 2High School Affiliated to Shanghai Jiao Tong University, Shanghai, 200441, China 3Applied Biology program, University of British Columbia, Vancouver, V6r3b1, Canada 4School of Chemical Machinery and Safety, Dalian University of Technology, Dalian, 116023, China †These authors contributed equally. Abstract: Human hereditary epilepsy has been found related to ion channel mutations in voltage-gated channels (Na+, K+, Ca2+, Cl-), ligand gated channels (GABA receptors), and G-protein coupled receptors, such as Mass1. In addition, some transmembrane proteins or receptor genes, including PRRT2 and nAChR, and glucose transporter genes, such as GLUT1 and SLC2A1, are also about the onset of epilepsy. The discovery of these genetic defects has contributed greatly to our understanding of the pathology of epilepsy. This review focuses on introducing and summarizing epilepsy-associated genes and related findings in recent decades, pointing out related mutant genes that need to be further studied in the future. 1 Introduction Epilepsy is a neurological disorder characterized by 2 Malfunction of Ion channel epileptic seizures caused by abnormal brain activity. 1 in Functional variation in voltage or ligand-gated ion 100 (50 million people) people are affected by symptoms channel mutations is a major cause of idiopathic epilepsy, of this disorder worldwide, with men, young children, and especially in rare genetic forms.
  • A Dissertation Entitled the Androgen Receptor

    A Dissertation Entitled the Androgen Receptor

    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
  • Ion Channels

    Ion Channels

    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.